Miragen Therapeutics (MGEN) Receives Daily Media Sentiment Score of 0.17
News coverage about Miragen Therapeutics (NASDAQ:MGEN) has trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Miragen Therapeutics earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave media coverage about the medical research company an impact score of 44.109865573083 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Miragen Therapeutics (MGEN) traded up $0.09 during trading on Tuesday, hitting $8.13. 79,800 shares of the stock traded hands, compared to its average volume of 175,714. The stock has a market cap of $181.38, a PE ratio of 54.20 and a beta of 1.91. Miragen Therapeutics has a 1-year low of $6.02 and a 1-year high of $18.00. The company has a current ratio of 7.11, a quick ratio of 7.11 and a debt-to-equity ratio of 0.04.
Miragen Therapeutics (NASDAQ:MGEN) last released its quarterly earnings data on Wednesday, November 8th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.39) by $0.12. The business had revenue of $1.63 million during the quarter, compared to analysts’ expectations of $0.72 million. Miragen Therapeutics had a negative net margin of 720.38% and a negative return on equity of 80.31%. sell-side analysts expect that Miragen Therapeutics will post -1.35 earnings per share for the current year.
In other news, Director Thomas E. Hughes sold 12,000 shares of Miragen Therapeutics stock in a transaction on Wednesday, December 20th. The shares were sold at an average price of $8.00, for a total transaction of $96,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 44.40% of the stock is currently owned by insiders.
About Miragen Therapeutics
Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.
Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.